Lan-Juan Li to Hepatitis B
This is a "connection" page, showing publications Lan-Juan Li has written about Hepatitis B.
Connection Strength
2.730
-
Establishment and development of national community-based collaborative innovation demonstration areas to achieve the control target of hepatitis B in China. BMC Infect Dis. 2019 Jul 12; 19(1):617.
Score: 0.432
-
Human cytomegalovirus and Epstein-Barr virus infections, risk factors, and their influence on the liver function of patients with acute-on-chronic liver failure. BMC Infect Dis. 2018 Nov 16; 18(1):577.
Score: 0.413
-
Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. World J Gastroenterol. 2018 Jul 28; 24(28):3181-3191.
Score: 0.404
-
Hepatitis B virus infection in hilly/mountainous regions of southeastern China: a locality-dependent epidemiology. BMC Infect Dis. 2017 12 29; 17(1):809.
Score: 0.388
-
Clinical features of treatment-naive patients with hepatitis B virus infection: A community-based survey from high- and intermediate-hepatitis B endemicity regions in Southeast China. Medicine (Baltimore). 2017 Apr; 96(16):e6660.
Score: 0.369
-
Prevalence of hepatitis B in insular regions of southeast China: a community-based study. PLoS One. 2013; 8(2):e56444.
Score: 0.277
-
Mutations in hepatitis B virus DNA from patients with coexisting HBsAg and anti-HBs. J Clin Virol. 2011 Nov; 52(3):198-203.
Score: 0.250
-
State of the art-Artificial liver in China. Artif Organs. 2019 Apr; 43(4):336-341.
Score: 0.106
-
Epidemiological features of and changes in incidence of infectious diseases in China in the first decade after the SARS outbreak: an observational trend study. Lancet Infect Dis. 2017 07; 17(7):716-725.
Score: 0.092